His comments/opinions have not prevented anyone from getting care.
You give him way too much credit.
The problem with AD drugs and drug candidates is that many have shown early promise only to fade longer term.
I wouldn't assume anything about the upcoming trials.
My comment has nothing to do with Alzheimer's patients and their struggles with the disease.
The initial poster stated he contacted the association urging them contact people who can stop the critics.
The Alzheimer's Association mission is to provide support for those afflicted, not to weigh in on comments/opinions of an ongoing clinical trial.
AXON hasn't conducted any studies. All data from trials for their drug were conducted when Glaxo owned the drug. AXON bought the drug for $5 million, did an IPO and is now recruiting patients in a phase III trial for RVT-101.
You're correct, the organization would care if the drug is helping patients (not proven yet, that's why they're conducting clinical trials).
Their mission statement, however doesn't seem to involve commenting on criticism of a drug or the company conducting the trials.
FYI, 2 patients dropped out (unrelated in Anavex 2-72).
As far as I know, the Anavex 2-73 trial continues unabated despite the criticism of certain individuals.
I don't think the Alzheimer's Association cares about the ongoing battle between supporters and critics.
I think they care about whether the drug is going to help patients.
Why should the Alzheimer's Organization care what's being said about a specific company or their drug?